BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32886943)

  • 1. Thyroglobulin Antibodies as a Prognostic Factor in Papillary Thyroid Carcinoma Patients with Indeterminate Response After Initial Therapy.
    Landenberger GMC; de Souza Salerno ML; Golbert L; de Souza Meyer EL
    Horm Metab Res; 2021 Feb; 53(2):94-99. PubMed ID: 32886943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
    Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study.
    Côrtes MCS; Rosario PW; Oliveira LFF; Calsolari MR
    Thyroid; 2018 Feb; 28(2):229-235. PubMed ID: 29325506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum antithyroglobulin antibody levels are not a good predictive factor on detection of disease activity in patients with papillary thyroid carcinoma.
    Turanli S; Mersin HH
    J Cancer Res Ther; 2020; 16(3):624-629. PubMed ID: 32719278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease activity in thyroglobulin-negative patients with papillary thyroid carcinoma.
    Hsieh CJ; Wang PW
    Thyroid; 2014 Mar; 24(3):488-93. PubMed ID: 23971786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can the follow-up of patients with papillary thyroid carcinoma of low and intermediate risk and excellent response to initial therapy be simplified using second-generation thyroglobulin assays?
    Rosario PW; Mourão GF; Calsolari MR
    Clin Endocrinol (Oxf); 2016 Oct; 85(4):596-601. PubMed ID: 26940991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
    Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
    Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Antithyroglobulin Antibody Concentrations Before and After Ablation with 131I as a Predictor of Structural Disease in Differentiated Thyroid Carcinoma Patients with Undetectable Basal Thyroglobulin and Negative Neck Ultrasonography.
    Rosario PW; Carvalho M; Mourão GF; Calsolari MR
    Thyroid; 2016 Apr; 26(4):525-31. PubMed ID: 26831821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating Antithyroglobulin Antibody As a Prognostic Marker for Differentiated Thyroid Cancer: A Meta-Analysis and Systematic Review.
    Lee ZJO; Eslick GD; Edirimanne S
    Thyroid; 2020 Nov; 30(11):1601-1612. PubMed ID: 32345152
    [No Abstract]   [Full Text] [Related]  

  • 11. Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection of serum thyroglobulin.
    Latrofa F; Ricci D; Montanelli L; Rocchi R; Piaggi P; Sisti E; Grasso L; Basolo F; Ugolini C; Pinchera A; Vitti P
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2380-7. PubMed ID: 22539585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients.
    Lamartina L; Montesano T; Trulli F; Attard M; Torlontano M; Bruno R; Meringolo D; Monzani F; Tumino S; Ronga G; Maranghi M; Biffoni M; Filetti S; Durante C
    Endocrine; 2016 Nov; 54(2):467-475. PubMed ID: 26668060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in serum thyroglobulin antibody levels as a dynamic prognostic factor for early-phase recurrence of thyroglobulin antibody-positive papillary thyroid carcinoma after total thyroidectomy.
    Yamada O; Miyauchi A; Ito Y; Nakayama A; Yabuta T; Masuoka H; Fukushima M; Higashiyama T; Kihara M; Kobayashi K; Miya A
    Endocr J; 2014; 61(10):961-5. PubMed ID: 25029954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indication for radioactive iodine in patients with papillary thyroid carcinoma without apparent disease after total thyroidectomy but with elevated antithyroglobulin antibodies.
    Ramos da Silva F; Rosario PW; Mourão GF
    Clin Endocrinol (Oxf); 2022 Jan; 96(1):82-88. PubMed ID: 34323308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of changes in serum thyroglobulin antibody levels of pre- and post-total thyroidectomy in thyroglobulin antibody-positive papillary thyroid carcinoma patients.
    Tsushima Y; Miyauchi A; Ito Y; Kudo T; Masuoka H; Yabuta T; Fukushima M; Kihara M; Higashiyama T; Takamura Y; Kobayashi K; Miya A; Kikumori T; Imai T; Kiuchi T
    Endocr J; 2013; 60(7):871-6. PubMed ID: 23585494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical significance of serum thyroglobulin and antithyroglobulin antibody in differentiated thyroid cancer after thyroid ablation].
    Vincze B; Sinkovics I; Keresztes S; Gergye M; Boér A; Remenár E; Péter I; Szentirmay Z; Kremmer T; Kásler M
    Magy Onkol; 2004; 48(1):27-34. PubMed ID: 15105893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum antithyroglobulin antibodies interfere with thyroglobulin detection in fine-needle aspirates of metastatic neck nodes in papillary thyroid carcinoma.
    Jeon MJ; Park JW; Han JM; Yim JH; Song DE; Gong G; Kim TY; Baek JH; Lee JH; Shong YK; Kim WB
    J Clin Endocrinol Metab; 2013 Jan; 98(1):153-60. PubMed ID: 23144473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
    Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
    Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma.
    Kim WG; Yoon JH; Kim WB; Kim TY; Kim EY; Kim JM; Ryu JS; Gong G; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2008 Dec; 93(12):4683-9. PubMed ID: 18812478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PROGNOSIS OF HIGH-RISK PAPILLARY THYROID CANCER PATIENTS WITH PRE-ABLATION STIMULATED TG <1 NG/ML.
    Tian T; Kou Y; Huang R; Liu B
    Endocr Pract; 2019 Mar; 25(3):220-225. PubMed ID: 30913010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.